Dr. Aditya Bagrodia, Dr. Tim Clinton and Dr. Eugene Pietzak discuss the use of pembrolizumab as an FDA-approved treatment. Dr. Bagrodia initiates the conversation by questioning the efficacy and benefits of pembrolizumab despite its approval. Dr. Pietzak describes how the drug is incorporated into clinical practice and the generally lukewarm reception it receives from both doctors and patients, citing low long-term response rates. Dr. Clinton adds that strict criteria apply to patient selection due to associated toxicities and limited clinical response. A biomarker-driven approach could improve enthusiasm and outcomes, although current biomarkers have not proven effective.
Watch the full episode on non-muscle-invasive bladder cancer: • Management of BCG-refr...
#bladdercancer #urologysurgery #urooncology #URO64